The healthcare industry’s most influential investment conference is almost here, are you ready? Every January, the J.P. Morgan Healthcare Conference sets the tone for the year ahead, shaping strategies, sparking partnerships, and driving investment decisions across the life sciences sector. To help you stay ahead, our expert analysts have created the #JPM2026 Preview Report, packed […]
Share:
Every January, the J.P. Morgan Healthcare Conference sets the tone for the year ahead, shaping strategies, sparking partnerships, and driving investment decisions across the life sciences sector.
To help you stay ahead, our expert analysts have created the #JPM2026 Preview Report, packed with insights you won’t want to miss.
Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.
Expect discussions on AI-driven drug discovery, cross-border biotech partnerships, and the evolving competitive landscape in high-growth therapeutic areas such as immunology, oncology, neuroscience, and rare diseases. Companies will also spotlight lifecycle management strategies and capital allocation priorities.
The conference provides early visibility into late-stage assets, regulatory catalysts, and emerging modalities like RNAi, gene editing, and antibody-drug conjugates. These insights help teams benchmark competitive positioning, identify gaps in therapeutic coverage, and align investment priorities with market trends.
Immunology, oncology, and metabolic disorders remain top targets, alongside rare diseases and advanced platforms such as cell and gene therapy. Companies are actively seeking assets that complement existing franchises or enable entry into high-value markets with unmet medical needs.
AI is moving beyond theoretical promise to practical application, accelerating clinical trial design, molecule discovery, and predictive analytics for regulatory success. For BD&L teams, understanding which companies are embedding AI into their R&D workflows is critical for assessing future partnership potential.
